Jordan

BMI View: Despite the revenue restricting effects of the Arab Spring, the prospects of a second global recession and the Eurozone sovereign debt crisis, BMI believes Hikma Pharmaceuticals'... 2011-10-07

BMI View: Despite the revenue restricting effects of the Arab Spring, the prospects of a second global recession and the Eurozone sovereign debt crisis, BMI believes Hikma Pharmaceuticals'... 2011-10-07

BMI View: We believe that complying with international intellectual property (IP) law has been a boon for Jordan's domestic pharmaceutical sector and pharmaceutical exports. It is no... 2011-08-19

BMI View: Jordan's dramatic loss of medical tourists since the start of the Middle East and North Africa (MENA) crisis could help private healthcare providers in the more stable states... 2011-06-16

Furthermore, we note that while Hikma is heavily exposed to the unrest in the MENA region, the company is attempting to increase its presence in the US and diversify its portfolio to... 2011-03-21

BMI View: While a plunge in Hikma Pharmaceuticals' share price has shown developments across Tunisia, Egypt, Libya and other markets in the Middle East and North Africa (MENA) region... 2011-03-02

BMI View: Jordan is a hub for pharmaceutical exports in the Middle East and has the strongest medical tourism sector in the region. There are investment opportunities in pharmaceutical... 2011-01-24

BMI View: We believe Jordanian drugmaker Hikma Pharmaceuticals' expansion of its genectables business to be a prudent strategy. Drugmakers can charge higher prices for injectable pharmaceuticals... 2010-11-03

BMI View: Lebanon's decision to allow the registration and therefore import of Jordanian medicines presents opportunities for Jordanian firms to expand regionally and also adds an... 2010-05-12

BMI's view on the Jordanian pharmaceutical market is set to hold for the short term - generic drugs will continue to comprise the majority of the drug market owing to the developed... 2010-04-27